

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

PROGENICS PHARMACEUTICALS INC
Form SC 13G/A
February 13, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 9)*

PROGENICS PHARMACEUTICALS, INC.

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

743187106

(CUSIP Number)

December 31, 2007

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 743187106

1) Names of Reporting Person

S.S. or I.R.S. Identification No. of Above Person

Tudor Investment Corporation

22-2514825

2) Check the Appropriate Box if a Member of a Group (See Instructions)

(a) -----

(b) X

3) SEC Use Only -----

4) Citizenship or Place of Organization Delaware

(5) Sole Voting Power 0

Number of Shares -----

Beneficially -----

Owned by Each -----

Reporting Person -----

With -----

(6) Shared Voting Power 2,107,881

(7) Sole Dispositive Power 0

(8) Shared Dispositive Power 2,107,881

9) Aggregate Amount Beneficially Owned
by Each Reporting Person

2,107,881

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) -----

11) Percent of Class Represented by Amount in Row 9 -----

7.1%

12) Type of Reporting Person (See Instructions) CO

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 743187106

1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Tudor Group Holdings LLC
13-3862746

2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) -----
(b) X

3) SEC Use Only -----

4) Citizenship or Place of Organization Delaware

	(5) Sole Voting Power	0
Number of Shares Beneficially Owned by Each Reporting Person With	(6) Shared Voting Power	234,507
	(7) Sole Dispositive Power	0
	(8) Shared Dispositive Power	234,507
	9) Aggregate Amount Beneficially Owned by Each Reporting Person	234,507

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) -----

11) Percent of Class Represented by Amount in Row 9 0.8%

12) Type of Reporting Person (See Instructions) 00

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

Page 3

CUSIP No. 743187106

1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Paul Tudor Jones, II

2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) -----
(b) X

3) SEC Use Only -----

4) Citizenship or Place of Organization USA

	(5)	Sole Voting Power	546,125
Number of Shares			
Beneficially	(6)	Shared Voting Power	2,342,388
Owned by Each			
Reporting Person	(7)	Sole Dispositive Power	546,125
With			
	(8)	Shared Dispositive Power	2,342,388

9) Aggregate Amount Beneficially Owned
by Each Reporting Person 2,888,513

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) -----

11) Percent of Class Represented by Amount in Row 9 9.7%

12) Type of Reporting Person (See Instructions) IN

CUSIP No. 743187106

1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Mark F. Dalton

2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) -----
(b) X

3) SEC Use Only -----

4) Citizenship or Place of Organization USA

	(5)	Sole Voting Power	159,000
Number of Shares			
Beneficially	(6)	Shared Voting Power	2,358,888
Owned by Each			
Reporting Person	(7)	Sole Dispositive Power	159,000
With			
	(8)	Shared Dispositive Power	2,358,888

9) Aggregate Amount Beneficially Owned
by Each Reporting Person 2,517,888

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

11) Percent of Class Represented by Amount in Row 9 8.5%

12) Type of Reporting Person (See Instructions) IN

CUSIP No. 743187106

1) Names of Reporting Person

S.S. or I.R.S. Identification No. of Above Person

The Tudor BVI Global Portfolio L.P. (f/k/a The Tudor BVI Global Portfolio Ltd.)

98-0223576

2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a)

(b) X

3) SEC Use Only

4) Citizenship or Place of Organization Cayman Islands

(5) Sole Voting Power 0

Number of Shares

Beneficially

Owned by Each

Reporting Person

With

(6) Shared Voting Power 1,820,068

(7) Sole Dispositive Power 0

(8) Shared Dispositive Power 1,820,068

9) Aggregate Amount Beneficially Owned
by Each Reporting Person

1,820,068

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

11) Percent of Class Represented by Amount in Row 9

6.1%

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

12) Type of Reporting Person (See Instructions) PN

Page 6

CUSIP No. 743187106

1) Names of Reporting Person

S.S. or I.R.S. Identification No. of Above Person

Tudor Arbitrage Partners L.P.

13-3496979

2) Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b) X

3) SEC Use Only

4) Citizenship or Place of Organization Delaware

(5) Sole Voting Power 0

Number of Shares
Beneficially
Owned by Each
Reporting Person
With

(6) Shared Voting Power 193,126

(7) Sole Dispositive Power 0

(8) Shared Dispositive Power 193,126

9) Aggregate Amount Beneficially Owned
by Each Reporting Person 193,126

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

11) Percent of Class Represented by Amount in Row 9 0.6%

12) Type of Reporting Person (See Instructions) PN

Page 7

CUSIP No. 743187106

1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Tudor Proprietary Trading, L.L.C.
13-3720063

2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) -----
(b) X

3) SEC Use Only

4) Citizenship or Place of Organization Delaware

	(5)	Sole Voting Power	0
Number of Shares Beneficially Owned by Each Reporting Person With	(6)	Shared Voting Power	25,981
	(7)	Sole Dispositive Power	0
	(8)	Shared Dispositive Power	25,981

9) Aggregate Amount Beneficially Owned by Each Reporting Person 25,981

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

11) Percent of Class Represented by Amount in Row 9 0.1%

12) Type of Reporting Person (See Instructions) 00

Page 8

CUSIP No. 743187106

1) Names of Reporting Person

S.S. or I.R.S. Identification No. of Above Person

Tudor Global Trading LLC

13-3862744

2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a)

(b) X

3) SEC Use Only

4) Citizenship or Place of Organization Cayman Islands

(5) Sole Voting Power 0

Number of Shares
Beneficially
Owned by Each
Reporting Person
With

(6) Shared Voting Power 208,526

(7) Sole Dispositive Power 0

(8) Shared Dispositive Power 208,526

9) Aggregate Amount Beneficially Owned
by Each Reporting Person 208,526

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

11) Percent of Class Represented by Amount in Row 9 0.7%

12) Type of Reporting Person (See Instructions) CO

Page 9

Item 1(a). Name of Issuer:

Progenics Pharmaceuticals, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

777 Old Saw Mill River Road
Tarrytown, NY 10591

Item 2(a). Name of Person Filing:

Tudor Investment Corporation ("TIC")
Tudor Group Holdings LLC ("TGH")
Paul Tudor Jones, II
Mark F. Dalton
The Tudor BVI Global Portfolio L.P. (f/k/a The Tudor BVI Global
Portfolio Ltd.) ("Tudor BVI")
Tudor Arbitrage Partners L.P. ("TAP")
Tudor Proprietary Trading, L.L.C. ("TPT")
Tudor Global Trading LLC ("TGT")

Item 2(b). Address of Principal Business Office or, if none, Residence:

The principal business office of each of TIC, TGH, TAP, TPT and TGT
is:

1275 King Street
Greenwich, CT 06831

The principal business office of each of Messrs. Jones and Dalton
is:

c/o Tudor Investment Corporation
1275 King Street
Greenwich, CT 06831

The principal business office of Tudor BVI is:

c/o CITCO
Kaya Flamboyan 9
Curacao, Netherlands Antilles

Item 2(c). Citizenship:

TIC is a Delaware corporation

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

Tudor BVI is a limited partnership organized under the laws of the Cayman Islands
Messrs. Jones and Dalton are citizens of the United States
TAP is a Delaware limited partnership
TGH, TPT and TGT are Delaware limited liability companies

Page 10

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number:

743187106

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:

- (a) Broker or Dealer registered under Section 15 of the Act
- (b) Bank as defined in section 3(a)(6) of the Act
- (c) Insurance Company as defined in Section 3(a)(19) of the Act
- (d) Investment Company registered under Section 8 of the Investment Company Act
- (e) Investment Adviser registered under section 203 of the Investment Advisers Act of 1940
- (f) Employment Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see ss.240.13d-1(b)(1)(ii)(F)
- (g) Parent Holding Company, in accordance with ss.240.13d-1(b)(1)(ii)(G) (Note: See Item 7)
- (h) Group, in accordance with ss.240.13d-1(b)(1)(ii)(H)

Item 4. Ownership (as of December 31, 2007).

- (a) Amount Beneficially Owned: See Item 9 of cover pages
- (b) Percent of Class: See Item 11 of cover pages
- (c) Number of shares as to which such person has:
 - (i) sole power to vote or to direct the vote See Item 5

of cover pages

 - (ii) shared power to vote or to direct the vote See Item 6

of cover pages

 - (iii) sole power to dispose or to direct the disposition of
See Item 7 of cover pages

 - (iv) shared power to dispose or to direct the disposition of
See Item 8 of cover pages

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

The shares of common stock ("Shares") reported herein as beneficially owned are owned directly by Tudor BVI (1,820,068 Shares), TAP (193,126 Shares), TPT (25,981 Shares), and TGT (15,400 Shares).

Because TIC provides investment advisory services to Tudor BVI, TIC may be deemed to beneficially own the Shares owned by Tudor BVI. TIC expressly disclaims beneficial ownership of such Shares. TGH holds a majority of the equity interests of TGT and indirectly holds a majority of the membership interests of TPT. TGH is also the sole limited partner of TAP.

Page 11

TGH expressly disclaims beneficial ownership of the Shares beneficially owned by each of such entities. TGT, as the sole general partner of TAP, may be deemed to beneficially own the Shares owned by TAP, and Mr. Dalton, as the sole general partner of D.F. Partners, a New York limited partnership, may be deemed to beneficially own the Shares owned by such entity. Each of TGT and Mr. Dalton expressly disclaim beneficial ownership of such Shares. Mr. Jones is the Chairman and principal equity owner of TIC and TGH. Mr. Jones expressly disclaims beneficial ownership of the Shares beneficially owned, or deemed beneficially owned, by such entities. Mr. Dalton is the Vice Chairman and President and an equity owner of TIC and TGH. Mr. Dalton expressly disclaims beneficial ownership of the Shares beneficially owned, or deemed beneficially owned, by such entities.

The Shares reported herein under Items 5 and 7 of Mr. Jones' cover page include 4,600 Shares held directly by Mr. Jones' individual retirement account. The Shares reported herein under Items 5 and 7 of Mr. Dalton's cover page include 85,000 immediately exercisable options.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parents Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

See cover pages

Item 9. Notice of Dissolution of Group.

Not applicable

Item 10. Certification.

Not applicable

Page 12

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2008

TUDOR INVESTMENT CORPORATION

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Associate General
Counsel

TUDOR GROUP HOLDINGS LLC

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Associate General
Counsel

/s/ Paul Tudor Jones, II

Paul Tudor Jones, II

/s/ Mark F. Dalton

Mark F. Dalton

THE TUDOR BVI GLOBAL PORTFOLIO L.P.

By: Tudor BVI GP Ltd.
Its:General Partner

By: Tudor Investment Corporation,
Trading Advisor

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Associate General
Counsel

Page 13

TUDOR ARBITRAGE PARTNERS L.P.

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

By: Tudor Global Trading LLC,
General Partner

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Associate General
Counsel

TUDOR PROPRIETARY TRADING, L.L.C.

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Associate General
Counsel

TUDOR GLOBAL TRADING LLC

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Associate General
Counsel